Everything below concerns systematic review. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Marine Police === Since the 2008 Mumbai attacks, the Government of India took the decision to strengthen coastal security and several important decisions were taken and launched a multi-tier arrangement for protection and maritime security of the country scheme. In April 2011, Government of India sanctioned 14 coastal police stations, surveillance equipment, computer systems, furniture and jetties for the West Bengal's share of the 157.50 km coastline under the Coastal Security Scheme Phase-II.
Upon his return from the U.S., Janež introduced the insulin pump method into clinical practice of treating adult patients with type 1 diabetes in Slovenia. Together with his colleagues from the Department of Endocrinology, Diabetes, and Metabolic Disease at University Medical Centre Ljubljana, Janež co-authored the algorithm used in insulin pump treatment, as well as tutored virtually all Slovenian diabetologists in usage of both insulin pump and glucose sensor. Janež also wrote all of the literature on subjects of functional insulin therapy and insulin pump in Slovenia, with its audiences ranging from diabetologists to patients. In 2008, he established a new unit for functional insulin therapy within the University Medical Centre. Janež also led the effort of forming international standards for interpretation of results obtained with glucose sensor, publishing and presenting these on several international diabetes-related symposiums. Coupled with his previous work in the field of functional insulin therapy and its pilot implementation in Slovenia, Janež went on to introduce this approach to diabetes treatment in other countries.
=== Manures and fertilizers === The blackcurrant requires a number of essential nutrients to thrive; nitrogen provides strong plant growth and stimulates the production of flower sprigs; phosphorus aids growth, the setting of fruit and crop yield; potassium promotes growth of individual shoots and increases the weight of individual fruits; magnesium is a constituent of chlorophyll and helps increase yields through interaction with potassium; calcium is required for cell division and enlargement and is particularly important for young plants and buds. An annual spring mulch of well rotted manure is ideal and poultry manure can also be used but needs prior composting with straw or other waste vegetable material. Spent mushroom compost can be used but care should be taken as it often contains lime and blackcurrants prefer slightly acidic soils. The blackcurrant is a gross feeder and benefits from additional nitrogen, and phosphatic and potash fertilisers should also be applied annually. A balanced artificial fertilizer can be used and a 10-10-10 granular product can be spread around the bushes at the rate of 100 to 240 grams (3+1⁄2 to 8+1⁄2 ounces) per plant. Weed growth can be suppressed with an organic mulch such as sawdust, bark, mushroom compost or straw, heavy plastic topped with an organic mulch cover or landscape fabric.
==== Ezetimibe ==== Ezetimibe is a selective cholesterol absorption inhibitor that inhibits the intestinal absorption of cholesterol by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal epithelium. This reduces the delivery of cholesterol to the liver, which then induces the upregulation of LDL receptor expression, lowering hepatic cholesterol stores and enhancing clearance of circulating LDL. More often prescribed as second-line therapy for dyslipidemia, ezetimibe is used in individuals with statin intolerance or those who failed to achieve the target LDL-C level on statin monotherapy. In particular, ezetimibe and statin dual therapy have shown a 15% greater LDL-C decrease compared with same-dose statins alone, favouring recovery from acute coronary syndrome. Whilst ezetimibe intolerance is uncommon, some reports have been made regarding gastrointestinal and musculoskeletal effects. Common adverse reactions of ezetimibe are nausea, abdominal pain, headache, fatigue, arthralgia, myalgia and hypersensitivity reactions. On rare occasions, ezetimibe may cause cholecystitis, pancreatitis, elevation of serum transaminase level and rhabdomyolysis. As hepatic impairment hinders the rate of ezetimibe metabolism by the liver, ezetimibe is not recommended in individuals with moderate or severe hepatic insufficiency due to prolonged systemic exposure to the drug. In addition, similar to combined statin and fibrate intake, individuals should avoid the concurrent use of ezetimibe with gemfibrozil as it would increase ezetimibe concentration in the body.
Sources: en.wikipedia.org
=== Snake identification === Identification of the snake is important in planning treatment in certain areas of the world but is not always possible. Ideally, the dead snake would be brought in with the person, but in areas where snake bite is more common, local knowledge may be sufficient to recognize the snake. However, in regions where polyvalent antivenoms are available, such as North America, identification of snakes is not a high-priority item. Attempting to catch or kill the offending snake also puts one at risk for re-envenomation or creating a second person bitten, and generally is not recommended. The three types of venomous snakes that cause the majority of major clinical problems are vipers, kraits, and cobras. Knowledge of what species are present locally can be crucial, as is knowledge of typical signs and symptoms of envenomation by each type of snake. A scoring system can be used to try to determine the biting snake based on clinical features, but these scoring systems are extremely specific to particular geographical areas and might be compromised by the presence of escaped or released non-native species.
== Terminology == Antigens can be proteins, polysaccharides, lipids, nucleic acids or other biomolecules. This includes parts (coats, capsules, cell walls, flagella, fimbriae, and toxins) of bacteria, viruses, and other microorganisms. Non-microbial non-self antigens can include pollen, egg white, and proteins from transplanted tissues and organs or on the surface of transfused blood cells.
The breasts are two prominences located on the upper ventral region of the torso in humans and other primates. Both sexes develop breasts from the same embryological tissues. The relative size and development of the breasts is a major secondary sex distinction between females and males. There is also considerable variation in size between individuals. Permanent breast growth during puberty is caused by estrogens in conjunction with the growth hormone. Female humans are the only mammals that permanently develop breasts at puberty; all other mammals develop their mammary tissue during the latter period of pregnancy. In females, the breasts contain mammary glands, which produce and secrete milk to feed infants. Subcutaneous fat covers and envelops a network of ducts that converge on the nipple, and these tissues give the breast its distinct size and globular shape. At the ends of the ducts are lobules, or clusters of alveoli, where milk is produced and stored in response to hormonal signals. During pregnancy, the breast responds to a complex interaction of hormones, including estrogens, progesterone, and prolactin, that mediate the completion of its development, namely lobuloalveolar maturation, in preparation of lactation and breastfeeding. Along with their major function in providing nutrition for infants, breasts can figure prominently in the perception of a woman's body and sexual attractiveness. Breasts, especially the nipples, can be an erogenous zone, and part of sexual activity.
Similarly, Sumo wrestlers are typically categorized by BMI as "severely obese" or "very severely obese", but one study of college-aged Sumo wrestlers found that 40% of them were no longer categorized as obese when body fat percentage (with a cutoff of <25%) was used instead of BMI; this was attributed to their very high lean body mass. The Edmonton Obesity Staging System (EOSS), developed in Canada, supplements BMI-based classification by incorporating medical, functional, and mental-health factors into a five-stage clinical framework.
The Riksdag (Swedish: [ˈrɪ̌ksdɑːɡ] or [ˈrɪ̌ksda], lit. 'diet of the realm') is the parliament and the supreme decision-making body of the Kingdom of Sweden. Since 1971, the Riksdag has been a unicameral parliament with 349 members (riksdagsledamöter), elected proportionally and serving, since 1994, fixed four-year terms. The 2026 Swedish general election is the most recent general election. The constitutional mandates of the Riksdag are enumerated in the Instrument of Government (Regeringsformen), and its internal workings are specified in greater detail in the Riksdag Act (Riksdagsordningen). The seat of the Riksdag is at Parliament House (Riksdagshuset), on the island of Helgeandsholmen in central Stockholm, in Gamla stan, the old town of Stockholm. The Riksdag has its institutional roots in the feudal Riksdag of the Estates, traditionally thought to have first assembled in Arboga in 1435. In 1866, following reforms of the 1809 Instrument of Government, that body was transformed into a bicameral legislature with an upper chamber (första kammaren) and a lower chamber (andra kammaren).
Sources: en.wikipedia.org
Plastocyanin is one of the family of blue copper proteins that are involved in electron transfer reactions. The copper-binding site is described as distorted trigonal pyramidal. The trigonal plane of the pyramidal base is composed of two nitrogen atoms (N1 and N2) from separate histidines and a sulfur (S1) from a cysteine. Sulfur (S2) from an axial methionine forms the apex. The distortion occurs in the bond lengths between the copper and sulfur ligands. The Cu−S1 contact is shorter (207 pm) than Cu−S2 (282 pm). The elongated Cu−S2 bonding destabilizes the Cu(II) form and increases the redox potential of the protein. The blue color (597 nm peak absorption) is due to the Cu−S1 bond where S(pπ) to Cu(dx2−y2) charge transfer occurs. In the reduced form of plastocyanin, His-87 will become protonated with a pKa of 4.4. Protonation prevents it acting as a ligand and the copper site geometry becomes trigonal planar.
=== Calreticulin === Calreticulin – especially its lectin-like domain – interacts with MHC-I. The P domain faces the MHC-I peptide-binding site towards ERp57. This orientation makes it possible for tapasin to attach and secure MHC-I. This translocation of TAP facilitates its opening out into an ER luminal cavity, edged by standard membrane entry points such as those for tapasin and MHC-I. These two entry points facilitate the recruitment of MHC-I with optimal peptide loading and eventual release of MHC-I in T-cell surfaces for recognition.
Actinic granuloma (O'Brien granuloma) Annular elastolytic giant cell granuloma (giant cell elastophagocytosis, Meischer's granuloma, Miescher's granuloma of the face) Annular sarcoidosis Benign cephalic histiocytosis (histiocytosis with intracytoplasmic worm-like bodies) Congenital self-healing reticulohistiocytosis (Hashimoto–Pritzker disease, Hashimoto–Pritzker syndrome) Erythrodermic sarcoidosis Generalized eruptive histiocytoma (eruptive histiocytoma, generalized eruptive histiocytosis) Generalized granuloma annulare Giant cell reticulohistiocytoma (solitary reticulohistiocytoma, solitary reticulohistiocytosis) Granuloma annulare in HIV disease Granuloma multiforme (Mkar disease, granuloma multiforme (Leiker)) Hand–Schüller–Christian disease Heerfordt's syndrome Hereditary progressive mucinous histiocytosis Hypopigmented sarcoidosis Ichthyosiform sarcoidosis Indeterminate cell histiocytosis Interstitial granulomatous drug reaction Langerhans cell histiocytosis (histiocytosis X) Letterer–Siwe disease Localized granuloma annulare Löfgren syndrome Lupus pernio Morpheaform sarcoidosis Mucosal sarcoidosis Multicentric reticulohistiocytosis Necrobiotic xanthogranuloma (necrobiotic xanthogranuloma with paraproteinemia) Non-X histiocytosis Papular sarcoid Papular xanthoma Patch-type granuloma annulare (macular granuloma annulare) Perforating granuloma annulare Progressive nodular histiocytosis Reticulohistiocytoma Scar sarcoid (sarcoidosis in scars) Sea-blue histiocytosis Subcutaneous granuloma annulare (deep granuloma annulare, pseudorheumatoid nodule) Subcutaneous sarcoidosis (Darier–Roussy disease, Darier–Roussy sarcoid) Systemic sarcoidosis Ulcerative sarcoidosis Xanthoma disseminatum (disseminated xanthosiderohistiocytosis, Montgomery syndrome)
Metabolites of MDMA that have been identified in humans include 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy-3-methoxyamphetamine (HMA), 3,4-dihydroxyamphetamine (DHA) (also called alpha-methyldopamine (α-Me-DA)), 3,4-dhydroxymethamphetamine (HHMA), 3,4-methylenedioxyphenylacetone (MDP2P), and 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH). The contributions of these metabolites to the psychoactive and toxic effects of MDMA are an area of active research. 80% of MDMA is metabolised in the liver, and about 20% is excreted unchanged in the urine. MDMA is known to be metabolized by two main metabolic pathways: (1) O-demethylenation followed by catechol-O-methyltransferase (COMT)-catalyzed methylation or glucuronide/sulfate conjugation; and (2) N-dealkylation, deamination, and oxidation to the corresponding benzoic acid derivatives conjugated with glycine. The metabolism may be primarily by cytochrome P450 (CYP450) enzymes CYP2D6 and CYP3A4 and COMT. Complex, nonlinear pharmacokinetics arise via autoinhibition of CYP2D6 and CYP2D8, resulting in zeroth order kinetics at higher doses. It is thought that this can result in sustained and higher concentrations of MDMA if the user takes consecutive doses of the drug.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.